Abstract:West Nile virus (WNV) is the leading cause of epidemic arboviral encephalitis in the United States. As there are currently no proven antiviral therapies or licensed human vaccines, understanding the neuropathogenesis of WNV is critical for rational therapeutic design. In WNV-infected mice, the depletion of microglia leads to enhanced viral replication, increased central nervous system (CNS) tissue injury, and increased mortality, suggesting that microglia play a critical role in protection against WNV neuroinvasive disease. To determine if augmenting microglial activation would provide a potential therapeutic strategy, we administered granulocyte-macrophage colony-stimulating factor (GM-CSF) to WNV-infected mice. Recombinant human GM-CSF (rHuGMCSF) (sargramostim [Leukine]) is an FDA-approved drug used to increase white blood cells following leukopenia-inducing chemotherapy or bone marrow transplantation. Daily treatment of both uninfected and WNV-infected mice with subcutaneous injections of GM-CSF resulted in microglial proliferation and activation as indicated by the enhanced expression of the microglia activation marker ionized calcium binding adaptor molecule 1 (Iba1) and several microglia-associated inflammatory cytokines, including CCL2 (C-C motif chemokine ligand 2), interleukin 6 (IL-6), and IL-10. In addition, more microglia adopted an activated morphology as demonstrated by increased sizes and more pronounced processes. GM-CSF-induced microglial activation in WNV-infected mice was associated with reduced viral titers and apoptotic activity (caspase 3) in the brains of WNV-infected mice and significantly increased survival. WNV-infected ex vivo brain slice cultures (BSCs) treated with GM-CSF also showed reduced viral titers and caspase 3 apoptotic cell death, indicating that GM-CSF specifically targets the CNS and that its actions are not dependent on peripheral immune activity. Our studies suggest that stimulation of microglial activation may be a viable therapeutic approach for the treatment of WNV neuroinvasive disease. IMPORTANCE Although rare, WNV encephalitis poses a devastating health concern, with few treatment options and frequent long-term neurological sequelae. Currently, there are no human vaccines or specific antivirals against WNV infections, so further research into potential new therapeutic agents is critical. This study presents a novel treatment option for WNV infections using GM-CSF and lays the foundation for further studies into the use of GM-CSF as a treatment for WNV encephalitis as well as a potential treatment for other viral infections.

WEST NILE VIRUS INFECTION OF PRIMARY MOUSE NEURONAL AND NEUROGLIAL CELLS: THE ROLE OF ASTROCYTES IN CHRONIC INFECTION

Chronic infection curtails the cytotoxic potential of acute T cell responses to West Nile virus in the brain

Persistent Infection and Associated Nucleotide Changes of West Nile Virus Serially Passaged in Hamsters

Osteopontin facilitates West Nile virus neuroinvasion via neutrophil “Trojan horse” transport

Phrenic nerve deficits and neurological immunopathology associated with acute West Nile virus infection in mice and hamsters

Increased Blood-Brain Barrier Permeability Is Not A Primary Determinant For Lethality Of West Nile Virus Infection In Rodents

Motor Unit Number Estimation As a Therapeutic Marker in Acute and Persistent West Nile Virus Infection in Hamsters

Nucleotide and Amino Acid Changes in West Nile Virus Strains Exhibiting Renal Tropism in Hamsters

Temporal tracking of microglial and monocyte single-cell transcriptomics in lethal flavivirus infection

Levels of Circulating NS1 Impact West Nile Virus Spread to the Brain

Persistent West Nile Virus Associated with a Neurological Sequela in Hamsters Identified by Motor Unit Number Estimation.

Autonomic Nervous Dysfunction In Hamsters Infected With West Nile Virus

Persistent West Nile Virus Infection in the Golden Hamster: Studies on Its Mechanism and Possible Implications for Other Flavivirus Infections

Differential susceptibility of human motor neurons to infection with Usutu and West Nile virus

Treatment with Granulocyte-Macrophage Colony-Stimulating Factor Reduces Viral Titers in the Brains of West Nile Virus-Infected Mice and Improves Survival

A Paradoxical Role for Neutrophils in the Pathogenesis of West Nile Virus

Neurological Approaches for Investigating West Nile Virus Disease and Its Treatment in Rodents

Persistence of West Nile Virus Infection in Vertebrates

Suitable Mouse Model to Study Dynamics of West Nile Virus Infection in Culex quinquefasciatus Mosquitoes

Matrix Metalloproteinase 9 Facilitates West Nile Virus Entry into the Brain

Differential Roles of Chemokines CCL2 and CCL7 in Monocytosis and Leukocyte Migration During West Nile Virus Infection